Alnylam Pharmaceuticals Inc Stock Price, News & Analysis

Alnylam (Nasdaq: ALNY) presented post hoc HELIOS-B analyses at AHA 2025 showing vutrisiran improved cardiac structure and function and preserved renal function in ATTR-CM patients.

Key imaging findings: CMR showed amyloid regression in 22% of treated patients vs 0% placebo at Year 3; mean ECV change was -0.10% with vutrisiran vs +7.86% with placebo (p=0.006). Renal results: fewer patients had ≥40% eGFR decline (12.7% vs 21.2%) and treatment reduced risk of death and CV events in patients progressing to CKD stage 4+ (HR 0.47; 95% CI 0.26–0.85).

Alnylam (Nasdaq: ALNY) said management will present company overviews at two investor conferences in November 2025:

• UBS Global Healthcare Conference — Monday, November 10, 2025 at 10:15 AM ET in Palm Beach Gardens, Florida
• Jefferies Global Healthcare Conference — Wednesday, November 19, 2025 at 11:30 AM GMT (6:30 AM ET) in London

Live audio webcasts of each presentation will be available on the Investors section of the company website and replays will be posted within 48 hours after each event.

Alnylam (NASDAQ: ALNY) reported Q3 2025 total net product revenues of $851M (103% YoY), driven by TTR revenues of $724M (135% YoY) led by AMVUTTRA. GAAP net income was $251M and non-GAAP net income was $396M for the quarter. The company raised 2025 guidance for the TTR franchise to $2,475M–$2,525M and total net product revenues to $2,950M–$3,050M.

Pipeline progress included HELIOS-B long‑term vutrisiran benefit data, start of ZENITH (zilebesiran) Phase 3 (~11,000 patients) and initiation of TRITON-PN; company reported a $300M Roche milestone and disclosed a U.S. Attorney subpoena related to government price reporting.

Alnylam (Nasdaq: ALNY) will report third-quarter 2025 financial results for the quarter ended September 30, 2025 on Thursday, October 30, 2025 before U.S. markets open.

Management will host a conference call and live audio webcast on October 30, 2025 at 8:30 AM ET to discuss results and outlook. The live webcast will be available on the company’s Investors events page at www.alnylam.com/events, and an archived webcast will be posted approximately two hours after the live event.

Alnylam Pharmaceuticals (Nasdaq: ALNY) has initiated the ZENITH Phase 3 cardiovascular outcomes trial for zilebesiran, dosing its first patient. The global study will evaluate zilebesiran as a biannual treatment for uncontrolled hypertension in approximately 11,000 patients across 35 countries.

The trial will assess zilebesiran's potential to reduce major adverse cardiovascular events in patients with uncontrolled hypertension who have established cardiovascular disease or are at high risk. This milestone has triggered a $300 million payment from partner Roche. Zilebesiran is an RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in the Renin-Angiotensin-Aldosterone System (RAAS), aiming to provide sustained blood pressure control with twice-yearly dosing.

Alnylam Pharmaceuticals (Nasdaq: ALNY) presented new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran) at the HFSA Annual Scientific Meeting 2025. The data showed that vutrisiran treatment led to 37-49% lower rates of gastrointestinal events in ATTR-CM patients compared to placebo.

Key findings include a 42% reduction in GI events in the overall population, with consistent benefits observed across monotherapy and baseline tafamidis groups. For specific symptoms like diarrhea, nausea, and vomiting, reductions of over 50% were observed. A separate analysis demonstrated a statistically significant 32% reduction in the risk of all-cause mortality and recurrent cardiovascular events through 36 months in the monotherapy group.

The study results supported recent approvals of AMVUTTRA for ATTR-CM treatment in multiple regions including the US, EU, and Japan, with over 8,000 patient-years of worldwide experience.

Illumina (NASDAQ: ILMN) and Nashville Biosciences announced that Alnylam Pharmaceuticals (NASDAQ: ALNY) has joined the Alliance for Genomic Discovery (AGD) as its ninth member. Alnylam, specializing in RNA interference therapeutics, will leverage the AGD's clinical genomic database to accelerate drug target discovery.

The partnership will contribute to expanding the database by adding 31,250 new whole-genomes to the existing 250,000 whole-genome cohort. The AGD dataset, completed in March 2025, combines diverse genomic data with longitudinal clinical phenotyping, utilizing Illumina's DRAGEN™ and Connected Analytics platforms for rapid analysis and insights generation.

Alnylam joins existing members including AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck, and Novo Nordisk in this collaborative effort to advance therapeutic discoveries, particularly in autoimmune and neurodegenerative diseases.

Alnylam Pharmaceuticals (Nasdaq: ALNY) has priced an upsized private offering of $575 million in 0.00% convertible senior notes due 2028. The offering, increased from the initially announced $500 million, includes an option for purchasers to buy an additional $86.25 million in notes.

The notes will mature on September 15, 2028, with an initial conversion price of $670.11 per share, representing a 40% premium above the reference price. Alnylam entered into capped call transactions to reduce potential dilution and will use approximately $30.7 million of the net proceeds for this purpose.

The company plans to use the remaining proceeds, along with cash on hand, to repurchase approximately $637.8 million of its existing 1.00% convertible senior notes due 2027, with a total repurchase cost of about $1.1 billion including accrued interest.

Alnylam Pharmaceuticals (Nasdaq: ALNY) has announced a private offering of $500 million convertible senior notes due 2028 to qualified institutional buyers. The company also granted initial purchasers an option for an additional $75 million in notes.

The notes will be senior, unsecured obligations with semi-annual interest payments, convertible to cash, common stock, or a combination at Alnylam's discretion. The company plans to enter into capped call transactions to reduce potential dilution and will use proceeds to repurchase a portion of its existing 1.00% convertible notes due 2027, with remaining funds for general corporate purposes.